This page is translated by Google and can contain errors. Go back to English.
  1. Home
  2. News

News

test

The Anticancer Fund supports EORTC trial in retroperitoneal sarcoma, a rare and aggressive cancer

The Anticancer Fund welcomes new members in the Advisory Board

Adoptive T cell therapy beneficial for metastatic melanoma patients that did not respond to standard of care immune therapy.

Els Verdegaal, Monique K van der Kooij, Marten Visser, Caroline van der Minne, Linda de Bruin, Pauline Meij, Anton Terwisscha van Scheltinga, Marij J Welters, Saskia Santegoets, Noel de Miranda, Inge Roozen, Gerrit Jan Liefers, Ellen Kapiteijn and Sjoerd H van der Burg (2020). Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. Journal for ImmunoTherapy of Cancer., Vol. 8, Issue 1. doi.org/10.1136/jitc-2019-000166

More than 200 trials to fight COVID-19 worldwide

First patient in PropAngio-trial for angiosarcoma

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infltrating lymphocytes in ovarian cancer

Christina Friese, Katja Harbst, Troels Holz Borch, Marie Christine Wulff Westergaard, Magnus Pedersen, Anders Kverneland, Göran Jönsson, Marco Donia, Inge Marie Svane, Özcan Met. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Sci Rep. 2020; 10: 3914. Published online 2020 Mar 3. doi: 10.1038/s41598-020-60738-4.